Refined Balloon Pulmonary Angioplasty in Chronic Thromboembolic Pulmonary Hypertension Initial Results of U.S. Regional Program

BACKGROUND Balloon pulmonary angioplasty (BPA) is rapidly evolving therapeutic option for patients with nonsurgical chronic thromboembolic pulmonary hypertension (CTEPH). There are few U.S. studies that have reported on the outcomes of this novel therapeutic option. OBJECTIVES The authors sought to evaluate the efficacy and safety of refined BPA in the treatment of patients with CTEPH. METHODS This is a retrospective study of CTEPH patients that underwent BPA. The primary efficacy endpoint was the change in pulmonary vascular resistance after BPA as compared to baseline and the primary safety endpoint was the rate of hemoptysis within 24 hours. Secondary endpoints included death, World Health Organization functional class, and 6minute walk distance. Logistic regression was used to evaluate factors associated with a hemodynamic and functional response. RESULTS A total of 211 BPA sessions were performed on 77 patients (average 2.7 +/- 1.7 sessions/patient). After BPA the mean pulmonary vascular resistance improved by 26% (6.5 +/- 3.4 WU to 4.8 +/- 2.9 WU, P < 0.001). The mean 6-minute walk distance improved by 71.7 m (P < 0.001), and WHO functional class improved by 1 functional class (P < 0.001). There was one death related to reperfusion lung injury. Ten sessions (4.7%) were complicated by hemoptysis. Independent factors associated with improved functional and hemodynamic response included preprocedural use of riociguat, reduce baseline PA compliance, and >3 BPA sessions/patient. CONCLUSIONS This single center study from the United States showed that BPA with refined techniques in patients with CTEPH was relatively safe and was associated with significant improvements in pulmonary hemodynamics and functional capacity. (c) 2023 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).